Can Electroporation Revive Gene Therapy?
Executive Summary
As regulators increase their scrutiny of viral vectors for gene therapy and set the bars for safety ever higher, some industry observers have begun questioning whether gene therapy will ever become a commercial reality. The difficulties in the field may turn out to be a life-saver for MaxCyte Inc. Its managers think their flow electroporation technology could be a platform for transforming patients' cells and getting them to produce a desired protein--without viruses, and the risks they bring.You may also be interested in...
Vical Leaves Gene Therapy for Vaccines
Is gene therapy ever going to become a routine, reliable method of disease treatment? It appears that the odds of success in anything like the near term are slimming. Now one of the first companies to get involved in gene therapy is finally giving up on it: San Diego-based Vical Inc., founded in 1987, recently announced its intention to use its naked DNA technology to develop a vaccine for cytomegalovirus (CMV).
TheraMed Inc.
To carry on work focusing on the oxygen-delivering capacity of red blood cells, EntreMed Inc, (best known for its anti-angiogenic molecules) created spin-off TheraMed Inc. TheraMed has developed a prototype device and is experimenting with different sorts of reagents, which it believes will enable the three basic sorts of blood cells--platelets, red cells and white blood cells--to be transformed into delivery vehicles for oxygen, drugs, and genes.
Health And Wellness Product Trademark Review 10 December, 2019
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports